Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02411201
Recruitment Status : Completed
First Posted : April 8, 2015
Results First Posted : March 9, 2017
Last Update Posted : March 9, 2017
Sponsor:
Information provided by (Responsible Party):
Guerbet

Brief Summary:

The main purpose of the study is to evaluate the pharmacokinetics of DOTAREM® in the body of children aged less than 2 years thanks to several blood samples (3 ml in total) taken following the administration of DOTAREM®.

DOTAREM® is a contrast agent commonly used for enhancement of Magnetic Resonance Imaging (MRI) to potentially improve the quality of the images and help the diagnosis. Children aged less than 2 years scheduled to undergo routine gadolinium-enhanced MRI of any body region may take part in the study. In this case they will receive DOTAREM®, a solution injected at the standard dose of 0.2mL/kg (0.1 mmol/kg) of body weight.


Condition or disease Intervention/treatment Phase
Magnetic Resonance Imaging Drug: DOTAREM Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
Study Start Date : March 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: MRI Scans

Arm Intervention/treatment
Experimental: DOTAREM Drug: DOTAREM
Single intravenous injection of 0.1 mmol/kg body weight
Other Name: gadoterate meglumine




Primary Outcome Measures :
  1. Area Under the Curve of DOTAREM in Plasma [ Time Frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Area under the curve was determined from typical and individual DOTAREM concentration-time profiles.

  2. Rate Constant of the Terminal Phase of DOTAREM [ Time Frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Rate constant of the terminal phase was determined from typical and individual DOTAREM concentration-time profiles.

  3. Terminal Elimination Half-life of DOTAREM From Plasma [ Time Frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Terminal elimination half-life was determined from typical and individual DOTAREM concentration-time profiles.

  4. Total Clearance of DOTAREM From Plasma [ Time Frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Total clearance was determined from typical and individual DOTAREM concentration-time profiles.

  5. Volume of Distribution of DOTAREM at Steady State [ Time Frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Volume of distribution at steady state was determined from typical and individual DOTAREM concentration-time profiles.


Secondary Outcome Measures :
  1. Simulated Plasma Concentration of DOTAREM [ Time Frame: at 10 and 20 min post-injection ]
    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method.

  2. MRI Lesion Visualization at Subject Level [ Time Frame: Pre-injection and post-injection (estimated between 5 and 20 minutes after injection) ]

    Lesion visualization was assessed on up to five most representative lesions per subject based on scoring of 3 co-endpoints:

    • border delineation (based on a 3-point scale where 1=none; 2=moderate and 3=clear and complete)
    • internal morphology (based on a 3-point scale where 1=poorly visible; 2=moderately visible and 3=sufficiently visible)
    • contrast enhancement (based on a 3-point scale where 1=none; 2=weak and 3=clear and bright)

    For each co-endpoint, a sum of scores was calculated at subject level as follows: sum of scores = score of the lesion 1 (+ score of the lesion 2 + score of the lesion 3 + score of the lesion 4 + score of the lesion 5, when applicable)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pediatric subject aged <2 years (term newborn infants to toddlers 23 months of age inclusive). Term is defined as ≥37 weeks of amenorrhea
  • Subject is scheduled to undergo routine gadolinium-enhanced MRI of any body region (e.g. CNS, cardiac) at the dose of 0.1 mmol/kg BW (0.2 mL/kg BW)
  • Subject with normal renal function for its age, estimated glomerular filtration rate calculated based on the Schwartz formula

Exclusion Criteria:

  • Subject planned for intervention (e.g. surgery) between the screening visit and up to 24 hours after DOTAREM injection
  • Subject whose preceding or subsequent treatment to DOTAREM injection (e.g., blood loss or receiving blood, treatment with diuretics, etc…) would alter DOTAREM pharmacokinetics parameters
  • Subject with subsequent planned treatment after DOTAREM injection that would prevent obtaining the required blood samples (e.g., emergency surgery, etc…)
  • Subject with a history of a bleeding disorder
  • Subject with severe liver disease (Child's Pugh Classification B or greater or serum direct bilirubin greater than 0.3 mg/dL, age adjusted)
  • Subject with electrolyte or fluid imbalance that presents undue risk
  • Subject undergoing a change in chemotherapy within 48 hours prior to and up to 24 hours after DOTAREM injection
  • Subject who received or will receive any other contrast agent within 72 hours prior to DOTAREM injection or up to 24 hours after DOTAREM injection
  • Subject with contraindication for MRI such as iron metal implants (e.g. aneurysm clips)
  • Subject with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents
  • Subject having participated within 30 days in a clinical study involving an investigational drug or device
  • Subject planned to participate simultaneously to another clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02411201


Locations
Layout table for location information
Austria
Landes-Frauen-und Kinderklinik Linz
Linz, Austria, 4020
France
CHU
Bordeaux, France, 33604
CHRU
Lille, France, 59037
Hôpital de Hautepierre
Strasbourg, France, 67098
Hungary
Department of Molecular and Neurological Clinical and Research Center
Budapest, Hungary, 1083
University of Debrecen Medical Center
Debrecen, Hungary, 4032
Borsod-Abaúj-Zemplén University County Hospital
Miskolc, Hungary, 3526
Poland
Uniwersytecki Szpital Dziecięcy w Lublinie
Lublin, Poland, 20093
Instytut Pomnik -Centrum Zdrowia Dziecka
Warszawa, Poland, 04730
Sponsors and Collaborators
Guerbet
Investigators
Layout table for investigator information
Study Director: Project Manager Guerbet

Layout table for additonal information
Responsible Party: Guerbet
ClinicalTrials.gov Identifier: NCT02411201    
Other Study ID Numbers: DGD-44-063
2013-003215-21 ( EudraCT Number )
First Posted: April 8, 2015    Key Record Dates
Results First Posted: March 9, 2017
Last Update Posted: March 9, 2017
Last Verified: January 2017